Platelet lysate suppresses the expression of lipocalin-type prostaglandin D2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells

Experimental Cell Research

Volumn 318, Issue 18, 2012, Pages 2284-2296

  Lange, Claudia ^a   Brunswig Spickenheier, Bärbel ^a   Eissing, Leah ^a   Scheja, Ludger ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adipocyte differentiation; Bone marrow; Lipocalin type prostagladin D2 synthase; Mesenchymal stromal cells; Platelet lysate

Indexed keywords

LIPOCALIN; LIPOCALIN TYPE PROSTAGLANDIN D2 SYNTHASE; PROSTAGLANDIN SYNTHASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; THROMBOCYTE;

EID: 84865300716     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.06.004     Document Type: Article

References (50)

1. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
2. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
3. Petite H., Viateau V., Bensaid W., Meunier A., de Pollak C., Bourguignon M., Oudina K., Sedel L., Guillemin G. Tissue-engineered bone regeneration. Nat. Biotechnol. 2000, 18:959-963.
4. Mahmood A., Lu D., Chopp M. Marrow stromal cell transplantation after traumatic brain injury promotes cellular proliferation within the brain. Neurosurgery 2004, 55:1185-1193.
5. Jaquet K., Krause K.T., Denschel J., Faessler P., Nauerz M., Geidel S., Boczor S., Lange C., Stute N., Zander A., Kuck K.H. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism?. Stem Cells Dev. 2005, 14:299-309.
6. Tögel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 2005, 289:F31-42.
7. Lange C., Togel F., Ittrich H., Clayton F., Nolte-Ernsting C., Zander A.R., Westenfelder C. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int. 2005, 68:1613-1617.
8. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., Marschall H.U., Dlugosz A., Szakos A., Hassan Z., Omazic B., Aschan J., Barkholt L., Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
9. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringdén O. Developmental committee of the European group for blood and marrow transplantation mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
10. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., Sussman M., Orchard P., Marx J.C., Pyeritz R.E., Brenner M.K. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 1999, 5:309-313.
11. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I., Lazarus H.M. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 2000, 18:307-316.
12. Chen S.L., Fang W.W., Ye F., Liu Y.H., Qian J., Shan S.J., Zhang J.J., Chunhua R.Z., Liao L.M., Lin S., Sun J.P. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol. 2004, 94:92-95.
13. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
14. Gooch A., Doty J., Flores J., Swenson L., Toegel F.E., Reiss G.R., Lange C., Zander A.R., Hu Z., Poole S., Zhang P., Westenfelder C. Initial report on a phase I clinical trial: prevention and treatment of post-operative acute kidney injury with allogeneic mesenchymal stem cells in patients who require on-pump cardiac surgery. Cell. Ther. Transplant. 2008, 1:31-35.
15. Kunter U., Rong S., Boor P., Eitner F., Müller-Newen G., Djuric Z., van Roeyen C.R., Konieczny A., Ostendorf T., Villa L., Milovanceva-Popovska M., Kerjaschki D., Floege J. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J. Am. Soc. Nephrol. 2007, 18:1754-1764.
16. Lange C., Cakiroglu F., Spiess A.N., Cappallo-Obermann H., Dierlamm J., Zander A.R. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J. Cell Physiol. 2007, 213:18-26.
17. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D.J., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy 2006, 8:315-317.
18. Lange C., Schroeder J., Lioznov M.V., Zander A.R. High-potential human mesenchymal stem cells. Stem Cells Dev. 2005, 14:70-80.
19. Rosen E.D., Hsu C.H., Wang X., Sakai S., Freeman M.W., Gonzalez F.J., Spiegelman B.M. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002, 16:22-26.
20. Rosen E.D. The transcriptional basis of adipocyte development. Prostaglandins Leukotr. Essent. Fatty Acids 2005, 73:31-34.
21. Rosen E.D., MacDougald O.A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell. Biol. 2006, 7:885-896.
22. Fujimori K., Aritake K., Urade Y. A novel pathway to enhance adipocyte differentiation of 3T3-L1 cells by up-regulation of lipocalin-type prostaglandin D synthase mediated by liver X receptor-activated sterol regulatory element-binding protein-1c. J. Biol. Chem. 2007, 282:18458-18466.
23. Maesaka J.K., Palaia T., Frese L., Fishbane S., Ragolia L. Prostaglandin D(2) synthase induces apoptosis in pig kidney LLC-PK1 cells. Kidney Int. 2001, 60:1692-1698.
24. Bachmeier M., Löffler G. Influence of growth factors on growth and differentiation of 3T3-L1 preadipocytes in serum-free conditions. Eur. J. Cell Biol. 1995, 68:323-329.
25. Tanaka T., Urade Y., Kimura H., Eguchi N., Nishikawa A., Hayaishi Lipocalin-type O. prostaglandin D synthase (L-trace) is a newly recognized type of retinoid transporter. J. Biol. Chem. 1997, 272:15789-15795.
26. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1997, 272:3406-3410.
27. Cho M.C., Lee H.S., Kim J.H., Choe Y.K., Hong J.T., Paik S.G., Yoon D.Y. A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma. J. Biochem. Mol. Biol. 2003, 36:207-213.
28. Siersbaek R., Nielsen R., Mandrup S. PPARgamma in adipocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Lett. 2010, 584:3242-3249.
29. Muruganandan S., Roman A.A., Sinal C.J. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell. Mol. Life Sci. 2009, 66:236-253.
30. Lefterova M.I., Zhang Y., Steger D.J., Schupp M., Schug J., Cristancho A., Feng D., Zhuo D., Stoeckert C.J., Liu X.S., Lazar M.A. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 2008, 22:2941-2952.
31. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994, 8:1224-1234.
32. Herrera R., Ro H.S., Robinson G.S., Xanthopoulos K.G., Spiegelman B.M. A direct role for C/EBP and the AP-I-binding site in gene expression linked to adipocyte differentiation. Mol. Cell. Biol. 1989, 9:5331-5339.
33. Shimizu M., Akter M.H., Emi Y., Sato R., Yamaguchi T., Hirose F., Osumi T. Peroxisome proliferator-activated receptor subtypes differentially cooperate with other transcription factors in selective transactivation of the perilipin/PEX11 alpha gene pair. J. Biochem. 2006, 139:563-573.
34. Gross D.N., Farmer S.R., Pilch Glut P.F. storage vesicles without Glut4: transcriptional regulation of insulin-dependent vesicular traffic. Mol. Cell. Biol. 2004, 24:7151-7162.
35. Huang Z.H., Reardon C.A., Mazzone T. Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes 2006, 55:3394-3402.
36. Horton J.D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 2002, 30:1091-1095.
37. Darimont C., Avanti O., Zbinden I., Leone-Vautravers P., Mansourian R., Giusti V., Macé K. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 2006, 88:309-318.
38. Baranowski M. Biological role of liver X receptors. J. Physiol. Pharmacol. 2008, 59(7):31-55.
39. Chowdhury A.A., Hossain M.S., Rahman M.S., Nishimura K., Jisaka M., Nagaya T., Shono F., Yokota K. Sustained expression of lipocalin-type prostaglandin D synthase in the antisense direction positively regulates adipogenesis in cloned cultured preadipocytes. Biochem. Biophys. Res. Commun. 2011, 411:287-292.
40. Hossain M.S., Chowdhury A.A., Rahman M.S., Nishimura K., Jisaka M., Nagaya T., Shono F., Yokota K. Stable expression of lipocalin-type prostaglandin D synthase in cultured preadipocytes impairs adipogenesis program independently of endogenous prostanoids. Exp. Cell Res. 2012, 318:408-415.
41. Ragolia L., Palaia T., Hall C.E., Maesaka J.K., Eguchi N., Urade Y. Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice. J. Biol. Chem. 2005, 280:29946-29955.
42. Tanaka R., Miwa Y., Mou K., Tomikawa M., Eguchi N., Urade Y., Takahashi-Yanaga F., Morimoto S., Wake N., Sasaguri T. Knockout of the l-pgds gene aggravates obesity and atherosclerosis in mice. Biochem. Biophys. Res. Commun. 2009, 378:851-856.
43. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83:813-819.
44. de Souza C.J., Eckhardt M., Gagen K., Dong M., Chen W., Laurent D., Burkey B.F. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001, 50:1863-1871.
45. Mazid M.A., Chowdhury A.A., Nagao K., Nishimura K., Jisaka M., Nagaya T., Yokota K. Endogenous 15-deoxy-Delta(12,14)-prostaglandin J(2) synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett. 2006, 580:6885-6890.
46. Styner M., Sen B., Xie Z., Case N., Rubin J. Indomethacin promotes adipogenesis of mesenchymal stem cells through a cyclooxygenase independent mechanism. J. Cell. Biochem. 2010, 111:1042-1050.
47. Hirawa N., Uehara Y., Yamakado M., Toya Y., Gomi T., Ikeda T., Eguchi Y., Takagi M., Oda H., Seiki K., Urade Y., Umemura S. Lipocalin-type prostaglandin D synthase in essential hypertension. Hypertension 2002, 39:449-454.
48. Urade Y., Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim. Biophys. Acta 2000, 1482:259-271.
49. Ragolia L., Hall C.E., Palaia T. Lipocalin-type prostaglandin D(2) synthase stimulates glucose transport via enhanced GLUT4 translocation. Prostaglandins Other Lipid Mediat. 2008, 87:34-41.
50. Tontonoz P., Singer S., Forman B.M., Sarraf P., Fletcher J.A., Fletcher C.D., Brun R.P., Mueller E., Altiok S., Oppenheim H., Evans R.M., Spiegelman B.M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:237-241.